New research reveals that patients who come off new GLP-1 drugs like Mounjaro or Wegovy can put back on reduced body mass far faster than those who stop traditional diet and exercise programs.
Published data in a leading medical journal demonstrates that while obese people can lose substantial amounts of their body weight while on the medication, the weight returns at an average rate of 0.8 kg per month upon discontinuation.
"Individuals using these drugs must be cognizant of the potential of fast weight regain when the treatment concludes," cautioned lead investigator Dr. Susan Jebb.
That rate of recovery suggests a reversion to pre-treatment weight within about one and a half years.
Analyzing Therapies
The analysis, which examined dozens of trials involving thousands of patients, contrasted the results of the injectable medications with older methods.
Scientists note that people who lose weight through dieting generally have a slower weight regain—around 0.1 kg a month—once they finish.
The Reason for the Quick Rebound
Nutrition scientists propose the way of the injections is key to understanding the accelerated weight return.
The injections copy a body's own chemical called GLP-1, which moderates feelings of fullness.
"Artificially providing GLP-1 concentrations far above than the body's typical production could lead to the body to produce less of its own natural hormone, and may also diminish sensitivity to its actions," said Dr. Adam Collins, a dietetics specialist.
"Discontinuation of this medication means appetite is no longer kept in check, making binge eating much more probable."
A Chronic Disease?
Medical guidelines suggest the jabs for individuals with weight-linked health risks, alongside recommended diet and exercise modifications.
Professionals argue that, considering the likelihood of weight regain, the therapy is often long-term.
This view is reinforced by drug manufacturers, who say that the results "emphasize the long-term character of excess weight," similar to managing conditions like hypertension.
Patient Testimonies
Users who have stopped the jabs explain a sudden return of appetite.
"I experienced something flipping and you become starving," recalled a patient.
The struggle is worsened if users have not adopted lasting dietary or behavioural modifications during treatment.
Widespread Interest
Figures show that a significant number of people in the UK have tried these injections in the last 12 months, with interest being substantial.
- Use is higher among females than males.
- The 40s and 50s age group shows the highest level of interest.
- A large proportion obtain the medications through private healthcare rather than the NHS.
In conclusion, clinicians stress that while these medications are potent agents for weight loss, they are not a permanent solution and long-term success likely depends on integrated behavioural changes.
